Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis

Abstract Not Availabl

The Citation and Articles Published in the TURKDERM Between 1999-2007: A Retrospective Assesment

Background and Design: In this report, it has been aimed to investigate the citation rates of the online issues of the "Turkdem" which has been indexed in the Web of Science since 2008. It is aimed also to have a base to comparing with the results of the citations in the indexed years after 2008 in the future

Validity and reliability of the Turkish version of Psoriasis Epidemiology Screening Tool for the detection of psoriatic arthritis in patients with psoriasis

Objectives: The Psoriasis Epidemiology Screening Tool (PEST) is a simple and useful questionnaire designed to screen arthritis in patients with psoriasis. This study aims to evaluate the validity and reliability of the PEST questionnaire in Turkish patients with psoriasis. Patients and methods: Between August 2019 and September 2019, a total of 158 adult patients with psoriasis (61 males, 68 females; mean age: 43.1 +/- 13.3 years; range, 29.8 to 56.4 years) who were not previously diagnosed with PsA were included. The testing procedure for translation and cultural adaptation was carried out according to the following steps: preparation, forward translation, reconciliation, back-translation/back-translation review, harmonization, finalization, and proofreading. Patients' demographic parameters, comorbidities, PEST, and Toronto Psoriatic Arthritis Screen (ToPAS 2) results were recorded. The patients were, then, assessed by a rheumatologist who was blinded to their PEST scores. The diagnosis of PsA was made according to the Classification criteria for Psoriatic Arthritis (CASPAR). The receiver operating characteristic (ROC) was assessed to obtain the sensitivity and specificity of the PEST questionnaire. Results: Of the patients, 42 had PsA, while 87 did not. Each parameter of PEST showed a low-high internal consistency ranging from 0.366 to 0.781. When the Question 3 was excluded, Cronbach alpha value increased to 0.866. The Cronbach alpha value of the whole scale was 0.829. The test-retest reliability of the Turkish version of PEST was determined as 0.86 for the total score (ICC=0.86 6 95% CI: 0.601-0.955; p0.0001). There was a strong positive correlation between PEST and ToPAS 2 (r=0.763; p0.001) and a moderate positive correlation between PEST and CASPAR (r=0.455; p0.001). A cut-off value of >= 3 yielded a sensitivity of 93% and a specificity of 89% for the diagnosis of PsA with the highest Youden's index. The PEST scale was found to have a higher sensitivity, but lower specificity in the head-to-head comparison with ToPAS 2. Conclusion: The Turkish version of PEST is a reliable and valid tool for screening PsA in Turkish patients with psoriasis

The Cases with Paederus Dermatitis From Denizli Region

Background and Objective: Paederus dermatitis is a self-limited skin disorder characterized with lineer and vesicular, bullous and/or pustular lesions on erythematous bases caused by Paederus species belonging to Staphlinidae (Coleoptera) family. The lesions which are seen in warm and moist climates especially in summer months occur within 24 hours after the crushing of the beetle over the skin and heal with slight hyperpigmentation within 7-8 days. In our study we aimed to evaluate the history and clinical features of cases with Paederus dermatitis

The Effects of Changing Lifestyle and Daily Behaviours in the First Months of COVID-19 Outbreak on Dermatological Diseases: Retrospective Cross-Sectional Observational Study

Objective: COVID-19 disease caused panic, fear of death, anxiety in people at the beginning of pandemic. This situation has dramatically changed people's lifestyle and daily behavior. The aim of our study was to determine the effects of changing lifestyle and daily behaviours on dermatological diseases in the first months of outbreak. Material and Methods: The diagnosis of the first patient with COVID- 19 in Turkey was established on 11 March 2020.In the same period, between 11 March and 30 April of 2020 and 2019, 454 versus 2.903 patients were admitted to the dermatology outpatient clinic and included in the study. The rates of dermatological diseases were compared. Pearson's chi-square test was used for statistical analysis. Results: Most of the patients were women (59.2 and 64.8%), and the average ages of the patients were 36.6±17.5 and 35.1±18.2 years for these time periods. Although admission to the hospital for those under 20 years of age due to curfew was decreased (16.8-10.1%), acne frequency increased (18.6- 21.1%, p=0.198). The frequency of psoriasis among papulosquamous diseases significantly increased (p=0.016). Urticaria (4.33-9.47%, p0.001), drug eruptions (0.17-1.32%, p0.001), and dermatitis and eczema (25.52-30.44%, p=0.025) significantly increased. The frequency of alopecia areata among hair disorders significantly increased (p=0.005). Rosacea (1.59-0.44%, p=0.05), bacterial infections (1.45- 0.44%, p=0.046), fungal infections (5.29-3.3%,p=0.042) and xerosis cutis (6.26-1.1%, p=0.025) significantly decreased. Admissions due to benign skin diseases (1.38-0%, p=0.012) significantly decreased. Conclusion: We consider that this study will contribute to providing the needed-evidence for the prevention and treatment of dermatological comorbidities by helping to identify the effects of changing lifestyles and daily behaviours on dermatological diseases because of the novel experimental environment created by the COVID-19 outbreak. © 2022 OrtadogŸu Reklam Tanitim Yayincilik Turizm Egitim Insaat Sanayi ve Ticaret A.S.. All rights reserved

The use of interferon-alpha 2a as monotherapy in stage IB patients with mycosis fungoides: A retrospective chart review of patient outcomes

The aim of this study was to evaluate the response to IFN-alpha 2a treatment as monotherapy in stage IB patients with mycosis fungoides (MF) in second-line therapy. Twenty-five patients with recurrent or persistent MF were included in the study. The diagnosis of MF was established according to clinical and histopathological signs. Clinical staging was made using TNMB classification. IFN-alpha 2a as monotherapy was used as treatment. IFN-alpha 2a was administered at a dose of 3 x 10(6) units thrice a week subcutaneously as initially described. According to clinical tolerance, the dose was increased every 4 weeks to 6 - 9 x 10(6) units. IFN-alpha 2a was used more frequently for at least 3 months after complete remission. Treatment success was evaluated with Clinical Response (disappearance of all clinical evidence = Complete Remission [CR], >= 50% decrease in extent or severity = Partial Remission [PR], unresponsiveness to treatment = Stable Disease [SD], progression of MF = Progressive Disease [PD]). The average age was 51.3 +/- 9.1. CR and PR were achieved in 11 (44%) and 12 (48%) patients, respectively. PD was observed in two (8%) patients. CR was accomplished at 16.1 +/- 9.8 weeks. Recurrences were mostly observed within 1 year (10.4 +/- 7.7 months). The recurrence rate was 45.4%. The mean duration of CR was 33.3 +/- 7.9 months. Side effects were seen in 36% of the patients (18.2% in CR). The most common side effect was fatigue (12%). The patients received 11 different types of treatment before IFN-alpha 2a treatment. The most frequent therapy prior to IFN-alpha 2a treatment was narrow-band ultraviolet-B (NB-UVB) phototherapy (15 [60%] patients). CR can be achieved in a relatively short period of time in patients receiving IFN-alpha 2a in MF. The duration of CR is reasonable. The side effects of IFN-alpha 2a are acceptable. Therefore, IFN-alpha 2a as monotherapy is a good option in stage IB second-line MF therapy

Stevens-Johnson syndrome/toxic epidermal necrolysis overlap case possibly induced by COVID-19 vaccine

[No Abstract Available

Multicenter study evaluating the impact of COVID-19 outbreak on dermatology outpatients in Turkey

COVID-19 pandemic has a significant impact on public health, whether directly or indirectly. The first case was seen in Turkey on March 11, and the World Health Organization (WHO) declared a pandemic on March 12, 2020. The study aimed to document the effect of pandemic on dermatology outpatient clinics in Turkey. Fifteen tertiary hospitals from 13 provinces were included in the study, which was conducted between January 12 and May 12, 2020. The International Codes of Diseases (ICD-10) categories and patients' characteristics were evaluated before and after the pandemic. A total of 164 878 patients, 133 131 before and 31 747 after the pandemic, were evaluated. The daily hospital applications were found reduced by 77%. The three of the most frequent diagnoses; dermatitis, acne, and psoriasis remained unchanged after the pandemic. While the frequency of herpes zoster, scabies, urticaria, pityriasis rosea and sexually transmitted diseases increased significantly; allergic and irritant contact dermatitis decreased after the pandemic. The applications regarding cutaneous neoplasms were considerably reduced during the pandemic, and this effect was more pronounced in cities with higher COVID incidence. The pandemic caused a noteworthy reduction in the number of patients accessing dermatological care. The pandemic caused significant changes in the frequency of a wide range of dermatological diseases. The application of cutaneous neoplasms is considerably reduced after the pandemic, and this effect was more pronounced in cities where pandemics are frequent. Therefore, the pandemic has resulted on numerous impacts on many critical issues in dermatology and dermatological care

Are The Complement Gene Mutations Affecting Clinical Outcomes in Children With C3 Glomerulopathy ?

[No Abstract Available